Patents by Inventor Per Borgstrom

Per Borgstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL THERAPY FOR PROSTATE CARCINOMA
    Publication number: 20160022606
    Abstract: Disclosed herein are methods of inhibiting or delaying the growth of androgen-dependent prostate cancer, and/or inhibiting or delaying the onset of castration-resistant prostate cancer (CRPC) by administering naphthoquinone analogs, such as plumbagin, and specified hormone therapy agents, including selective inhibitors of 17,20-lyase activity of CYP 17.
    Type: Application
    Filed: March 5, 2014
    Publication date: January 28, 2016
    Inventor: Per BORGSTROM
  • Myeloid colony stimulating factor and uses thereof
    Publication number: 20110212074
    Abstract: The identification of the HYAL 1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5-may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: April 29, 2011
    Publication date: September 1, 2011
    Inventors: Gregory I. Frost, Per Borgstrom
  • ECTOPIC, ORTHOTOPIC MODEL FOR REVASCULARIZATION AND TUMOR ASSESSMENT
    Publication number: 20110173709
    Abstract: Improved vascularization and tumor models, comprising a test animal having a dorsal skin window chamber, and an exogenous tissue sample implanted ectopically in the skin within the window chamber, are described, as are methods of using the models.
    Type: Application
    Filed: February 29, 2008
    Publication date: July 14, 2011
    Inventors: Jan E. Schnitzer, Philip Oh, Per Borgstrom
  • Inhibition of Antigen Presentation with Poorly Catabolized Polymers
    Publication number: 20100331279
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Application
    Filed: August 31, 2010
    Publication date: December 30, 2010
    Inventors: Gregory I. Frost, Per Borgstrom
  • Inhibition of antigen presentation with poorly catabolized polymers
    Patent number: 7786096
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: August 31, 2010
    Assignee: Halozyme, Inc.
    Inventors: Greogry I. Frost, Per Borgstrom
  • Myeloid Colony Stimulating Factor and Uses Thereof
    Publication number: 20100184845
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5- may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: April 1, 2010
    Publication date: July 22, 2010
    Inventors: Gregory I. Frost, Per Borgstrom
  • Myeloid colony stimulating factor and uses thereof
    Patent number: 7718428
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5-hyaluronidase may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: May 18, 2010
    Assignee: Halozyme, Inc.
    Inventors: Gregory I. Frost, Per Borgstrom
  • Inhibition of Antigen Presentation with Poorly Catabolized Polymers
    Publication number: 20090215722
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Application
    Filed: May 8, 2009
    Publication date: August 27, 2009
    Inventors: Gregory I. Frost, Per Borgstrom
  • Inhibition of antigen presentation with poorly catabolized polymers
    Patent number: 7538097
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: May 26, 2009
    Assignees: Halozyme, Inc., Sidney Kimmel Cancer Center
    Inventors: Gregory I. Frost, Per Borgstrom
  • Myeloid colony stimulating factor and uses thereof
    Publication number: 20060247201
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5- may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: May 9, 2006
    Publication date: November 2, 2006
    Inventors: Gregory Frost, Per Borgstrom
  • Inhibition of antigen presentation with poorly catabolized polymers
    Publication number: 20040047874
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of celular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Application
    Filed: October 8, 2003
    Publication date: March 11, 2004
    Inventors: Gregory I. Frost, Per Borgstrom
  • Myeloid colony stimulating factor and uses thereof
    Publication number: 20030212021
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5 may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: November 26, 2002
    Publication date: November 13, 2003
    Inventors: Gregory I. Frost, Per Borgstrom